FDA Considers Approval for Moderna's mRNA Flu Vaccine

Why it matters locally: California, a major hub for biotechnology and pharmaceutical research, stands to be significantly impacted by the FDA's decision, potentially influencing investment, research, and manufacturing within the state's life sciences sector.

The Food and Drug Administration (FDA) is preparing to issue a ruling on Moderna's messenger RNA (mRNA) flu vaccine. This vaccine, if approved, would become the first mRNA-based influenza shot available commercially. Observers expect the FDA's decision to affect the biotechnology industry broadly.